news
A Takeda logo is seen in its research hub in Cambridge, Massachusetts, U.S., November 26, 2018. REUTERS/Julie Steenhuysen

Cleary Gottlieb Steen & Hamilton has advised Japanese pharmaceutical giant Takeda on its planned acquisition of U.S.-based Nimbus Therapeutics' experimental psoriasis drug, with Goodwin Procter acting for the seller.

The deal value is expected to be up to $6 billion, reported Reuters. It added that the drug, codenamed "NDI-034858", has shown statistically significant reduction in moderate-to-severe psoriasis in a mid-stage study and is expected to enter late-stage trials next year.

The Goodwin team was led by partners Bill Collins, Sarah Solomon and Yasin Akbari in Boston, and Erini Svokos in New York.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

NO&T, STB, AMT, Davis Polk advise on Japan's biggest IPO in 6 years

by Asian Legal Business《亚洲法律杂志》 |

Nagashima Ohno & Tsunematsu and Simpson Thacher & Bartlett have advised Tokyo Metro on its 348.6 billion yen ($2.3 billion) initial public offering, Japan's largest in six years.

Deals

CAM, Trilegal act on Adani’s latest $500mln QIP

by Nimitt Dixit |

Cyril Amarchand Mangaldas has represented Adani Enterprises, the Adani Group’s flagship entity, on its $500 million qualified institutional placement, with Trilegal advising the placement agents SBI Capital Markets, Jefferies India, and ICICI Securities.

Deals

CAM, Khaitan guide latest major India cement M&A

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising the Adani-held Ambuja Cement on its acquisition of 46.8 percent controlling stake in Orient Cement (OCL) for approximately $451 million. Khaitan & Co is representing OCL on the deal.